Eptifibatide

Inquiry

Cat Number

API188627807

CAS Number

188627-80-7

For research use only. We do not supply to patients.

For pharmaceutical-grade products or other inquiries, please contact our experts.

Product Detail Description Scientific Support Customer Q&A

CAS Number

188627-80-7

EINECS

641-366-7

Storage

Store at 2-8℃

Synonyms

Integrilin; Integrelin; Eptifibatida; DTXSID7046673

Molecular Formula

C35H49N11O9S2

Molecular Weight

832

Smiles

C1C[C@H]2C(=O)N[C@@H](CSSCCC(=O)N[C@H](C(=O)NCC(=O)N[C@H](C(=O)N[C@H](C(=O)N2C1)CC3=CNC4=CC=CC=C43)CC(=O)O)CCCCN=C(N)N)C(=O)N

Appearance

Sterile filtered white lyophilized powder

Melting Point

92-98℃

Relative Density

1.60±0.1 (Predicted)

General Description

Eptifibatide is a cyclic heptapeptide platelet glycoprotein IIb/IIIa receptor antagonist, administered intravenously for acute coronary syndromes. It is derived from the venom of the southeastern pygmy rattlesnake. The drug has a short half-life and is reversible, unlike some other agents in its class.

Mechanism of Action

Eptifibatide binds to the GP IIb/IIIa receptor on the surface of platelets, blocking the final common pathway of platelet aggregation—fibrinogen cross-linking between platelets. This inhibition is competitive and reversible, with platelet function returning within 4-8 hours after infusion stops. The drug does not affect other platelet receptors or coagulation factors. Its specificity for activated platelets reduces the risk of systemic bleeding.

Application

Eptifibatide is indicated for the treatment of acute coronary syndrome (unstable angina/NSTEMI) in patients managed with percutaneous coronary intervention (PCI), as well as for patients undergoing PCI (including stenting) when oral antiplatelet therapy is inadequate.

In an interventional study, 207 patients undergoing percutaneous coronary intervention (PCI) with stent implantation were randomized to receive a single intracoronary dose of eptifibatide or no eptifibatide (control). Outcomes within 24 hours — including cardiac death, stent thrombosis, myocardial infarction, target lesion/vessel revascularization, cerebrovascular accident, and emergency CABG — were low in both groups, with no statistically significant differences between groups (all P > 0.05). Single‑dose intracoronary eptifibatide did not provide additional benefit over standard PCI alone in these short‑term endpoints.

Fig. 1 Flow diagram of the study. (Shariati H, et al., 2016)

References

Shariati H, et al. Immediate outcomes of eptifibatide therapy during intracoronary stent implantation. Adv Biomed Res. 2016;5:204.

Does Eptifibatide require strict cold chain storage as a cyclic peptide?

Yes, it must be stored at 2-8°C. As a peptide with a disulfide bridge, it is thermally labile and prone to ring opening and aggregation at higher temperatures.

Is Eptifibatide sensitive to light during handling and storage?

Yes, it is photosensitive. Store in light-resistant containers and handle under subdued light to prevent photodegradation of the tryptophan residue.

What is the stability of Eptifibatide after reconstitution for intravenous use?

Reconstituted solutions have limited stability (typically 24 hours under refrigeration). We provide detailed in-use stability data for various diluents, including saline.

How is the purity of Eptifibatide confirmed given its peptide nature?

We use reverse-phase HPLC for chemical purity, SEC-HPLC for aggregates, and mass spectrometry for identity. The disulfide bridge integrity is verified by peptide mapping.